^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UM-164

    i
    Other names: UM-164
    Associations

    News

    Trials
    Company:
    University of Michigan
    Drug class:
    p38 inhibitor, cSRC inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity. (PubMed, Cancers (Basel))
    UM-164 shows stronger binding to the active sites of Src compared with the conventional Src inhibitor Dasatinib. Furthermore, the in vitro anti-glioma effect mediated by UM-164 was confirmed in a xenograft glioma model. Together, these findings reveal a mechanism by which UM-164 suppresses the malignant phenotypes of glioma cells and might provide a rationale for UM-164-based anti-glioma clinical trials.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • CCN1 (Cellular Communication Network Factor 1)
    |
    dasatinib • UM-164